Alveolar echinococcosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:284B67.6B67.7B67.5
Who is this for?
Show terms as
1Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Alveolar echinococcosis (AE) is a rare but serious parasitic disease caused by the larval stage of the tapeworm Echinococcus multilocularis. It is also known as alveolar hydatid disease or multilocular echinococcosis. Humans become infected accidentally by ingesting eggs of the parasite, typically through contact with infected foxes, dogs, or other definitive hosts, or by consuming contaminated food such as wild berries or vegetables. The disease is not inherited but acquired through environmental exposure. The parasite primarily affects the liver, where it forms tumor-like, infiltrative parasitic masses that grow slowly over years, often mimicking hepatic malignancy. The larval tissue proliferates by external budding, invading surrounding structures in a manner similar to a malignant tumor. If untreated, the disease can metastasize to distant organs including the lungs, brain, and bones. Key symptoms include upper abdominal pain, hepatomegaly, jaundice, weight loss, and fatigue. Because of its slow growth, the disease often has an asymptomatic incubation period of 5 to 15 years before clinical manifestation, and diagnosis is frequently made at an advanced stage. Treatment of alveolar echinococcosis requires a multidisciplinary approach. Radical surgical resection of the parasitic lesion, when feasible, remains the treatment of choice and offers the best chance of cure. Long-term antiparasitic therapy with benzimidazoles (primarily albendazole) is essential, both as adjunctive treatment following surgery and as the primary treatment for inoperable cases. Continuous albendazole therapy may be required for years or even lifelong in patients with non-resectable disease. Without treatment, the mortality rate is very high, exceeding 90% within 10 to 15 years of diagnosis. Early detection through screening programs in endemic areas and advances in imaging and serological diagnostics have improved outcomes. Liver transplantation may be considered in select cases with extensive hepatic involvement.

Also known as:

Clinical phenotype terms— hover any for plain English:

Hepatic cystsHP:0001407Low back painHP:0003419Epigastric painHP:0410019Abnormal sternum morphologyHP:0000766
Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Alveolar echinococcosis.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
N/A1 trial
Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis
N/A
Actively Recruiting
PI: Delphine VERHOEVEN-WEIL, MD (CHU Besançon) · Sites: Besançon · Age: 1899 yrs

Specialists

14 foundView all specialists →
CM
Carine RICHOU, MD
Specialist
PI on 1 active trial
DM
Delphine VERHOEVEN-WEIL, MD
Specialist
PI on 1 active trial
GM
Gulnara Minbaeva, MD
Specialist
PI on 1 active trial1 Alveolar echinococcosis publication
GP
Gerardo Blanco-Fernández, MD, PhD
Specialist
PI on 2 active trials
BM
Beat Müllhaupt 01 Studienregister MasterAdmins
Specialist
PI on 1 active trial4 Alveolar echinococcosis publications
MM
MEHMET KAPLAN, MD
Specialist
PI on 1 active trial
SW
sara WAGUAF
Specialist
PI on 2 active trials
YC
Yajin Chen
Specialist
PI on 1 active trial1530 Alveolar echinococcosis publications
PP
Paweł Sutkowy, PhD
Specialist
PI on 2 active trials
EM
Elena Zafirovikj, MD
Specialist
PI on 1 active trial
KM
Klaus Kaczirek, M.D.
Specialist
PI on 1 active trial
GM
Germano P Nascimento, MD
Specialist
PI on 1 active trial1 Alveolar echinococcosis publication
FG
Frédéric GRENOUILLET
Specialist
PI on 1 active trial
BG
Beate Grüner
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Alveolar echinococcosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Alveolar echinococcosisForum →

No community posts yet. Be the first to share your experience with Alveolar echinococcosis.

Start the conversation →

Latest news about Alveolar echinococcosis

Disease timeline:

New recruiting trial: IM Bands in Inactive Hepatic CE

A new clinical trial is recruiting patients for Alveolar echinococcosis

New recruiting trial: Biliary Fistulas in Surgery of Liver Echinococcosis

A new clinical trial is recruiting patients for Alveolar echinococcosis

New recruiting trial: Presentation of Protoscolexes and Acephalocysts in the Fibrous Capsule Area of the Liver With Echinococcosis

A new clinical trial is recruiting patients for Alveolar echinococcosis

New recruiting trial: Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis

A new clinical trial is recruiting patients for Alveolar echinococcosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Alveolar echinococcosis

What is Alveolar echinococcosis?

Alveolar echinococcosis (AE) is a rare but serious parasitic disease caused by the larval stage of the tapeworm Echinococcus multilocularis. It is also known as alveolar hydatid disease or multilocular echinococcosis. Humans become infected accidentally by ingesting eggs of the parasite, typically through contact with infected foxes, dogs, or other definitive hosts, or by consuming contaminated food such as wild berries or vegetables. The disease is not inherited but acquired through environmental exposure. The parasite primarily affects the liver, where it forms tumor-like, infiltrative para

At what age does Alveolar echinococcosis typically begin?

Typical onset of Alveolar echinococcosis is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Alveolar echinococcosis?

Yes — 1 recruiting clinical trial is currently listed for Alveolar echinococcosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Alveolar echinococcosis?

14 specialists and care centers treating Alveolar echinococcosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.